59 related articles for article (PubMed ID: 38487528)
21. IL-12 Family Cytokines in Cancer and Immunotherapy.
Mirlekar B; Pylayeva-Gupta Y
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33418929
[TBL] [Abstract][Full Text] [Related]
22. Localized Interleukin-12 for Cancer Immunotherapy.
Nguyen KG; Vrabel MR; Mantooth SM; Hopkins JJ; Wagner ES; Gabaldon TA; Zaharoff DA
Front Immunol; 2020; 11():575597. PubMed ID: 33178203
[TBL] [Abstract][Full Text] [Related]
23. Mechanisms regulating PD-L1 expression on tumor and immune cells.
Chen S; Crabill GA; Pritchard TS; McMiller TL; Wei P; Pardoll DM; Pan F; Topalian SL
J Immunother Cancer; 2019 Nov; 7(1):305. PubMed ID: 31730010
[TBL] [Abstract][Full Text] [Related]
24. The Expanding Role of Anti-IL-12 and/or Anti-IL-23 Antibodies in the Treatment of Inflammatory Bowel Disease.
Kashani A; Schwartz DA
Gastroenterol Hepatol (N Y); 2019 May; 15(5):255-265. PubMed ID: 31360139
[TBL] [Abstract][Full Text] [Related]
25. IL-12 Enhances Immune Response by Modulation of Myeloid Derived Suppressor Cells in Tumor Microenvironment.
Choi JN; Sun EG; Cho SH
Chonnam Med J; 2019 Jan; 55(1):31-39. PubMed ID: 30740338
[TBL] [Abstract][Full Text] [Related]
26. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.
Lee DW; Santomasso BD; Locke FL; Ghobadi A; Turtle CJ; Brudno JN; Maus MV; Park JH; Mead E; Pavletic S; Go WY; Eldjerou L; Gardner RA; Frey N; Curran KJ; Peggs K; Pasquini M; DiPersio JF; van den Brink MRM; Komanduri KV; Grupp SA; Neelapu SS
Biol Blood Marrow Transplant; 2019 Apr; 25(4):625-638. PubMed ID: 30592986
[TBL] [Abstract][Full Text] [Related]
27. Reviewing the role of healthy volunteer studies in drug development.
Karakunnel JJ; Bui N; Palaniappan L; Schmidt KT; Mahaffey KW; Morrison B; Figg WD; Kummar S
J Transl Med; 2018 Dec; 16(1):336. PubMed ID: 30509294
[TBL] [Abstract][Full Text] [Related]
28. First-in-Human Phase I Trial of a Tumor-Targeted Cytokine (NHS-IL12) in Subjects with Metastatic Solid Tumors.
Strauss J; Heery CR; Kim JW; Jochems C; Donahue RN; Montgomery AS; McMahon S; Lamping E; Marté JL; Madan RA; Bilusic M; Silver MR; Bertotti E; Schlom J; Gulley JL
Clin Cancer Res; 2019 Jan; 25(1):99-109. PubMed ID: 30131389
[TBL] [Abstract][Full Text] [Related]
29. Design and Conduct Considerations for First-in-Human Trials.
Shen J; Swift B; Mamelok R; Pine S; Sinclair J; Attar M
Clin Transl Sci; 2019 Jan; 12(1):6-19. PubMed ID: 30048046
[TBL] [Abstract][Full Text] [Related]
30. Harnessing albumin as a carrier for cancer therapies.
Hoogenboezem EN; Duvall CL
Adv Drug Deliv Rev; 2018 May; 130():73-89. PubMed ID: 30012492
[TBL] [Abstract][Full Text] [Related]
31. Revisiting Interleukin-12 as a Cancer Immunotherapy Agent.
Berraondo P; Etxeberria I; Ponz-Sarvise M; Melero I
Clin Cancer Res; 2018 Jun; 24(12):2716-2718. PubMed ID: 29549160
[TBL] [Abstract][Full Text] [Related]
32. Natural Killer Cell-Based Immunotherapy in Gynecologic Malignancy: A Review.
Uppendahl LD; Dahl CM; Miller JS; Felices M; Geller MA
Front Immunol; 2017; 8():1825. PubMed ID: 29354116
[TBL] [Abstract][Full Text] [Related]
33. Cytokines in Cancer Immunotherapy.
Waldmann TA
Cold Spring Harb Perspect Biol; 2018 Dec; 10(12):. PubMed ID: 29101107
[TBL] [Abstract][Full Text] [Related]
34. IL-12 protects from psoriasiform skin inflammation.
Kulig P; Musiol S; Freiberger SN; Schreiner B; Gyülveszi G; Russo G; Pantelyushin S; Kishihara K; Alessandrini F; Kündig T; Sallusto F; Hofbauer GF; Haak S; Becher B
Nat Commun; 2016 Nov; 7():13466. PubMed ID: 27892456
[TBL] [Abstract][Full Text] [Related]
35. Regulation of Interleukin-12 Production in Antigen-Presenting Cells.
Zheng H; Ban Y; Wei F; Ma X
Adv Exp Med Biol; 2016; 941():117-138. PubMed ID: 27734411
[TBL] [Abstract][Full Text] [Related]
36. New insights into IL-12-mediated tumor suppression.
Tugues S; Burkhard SH; Ohs I; Vrohlings M; Nussbaum K; Vom Berg J; Kulig P; Becher B
Cell Death Differ; 2015 Feb; 22(2):237-46. PubMed ID: 25190142
[TBL] [Abstract][Full Text] [Related]
37. Single low-dose rHuIL-12 safely triggers multilineage hematopoietic and immune-mediated effects.
Gokhale MS; Vainstein V; Tom J; Thomas S; Lawrence CE; Gluzman-Poltorak Z; Siebers N; Basile LA
Exp Hematol Oncol; 2014 Apr; 3(1):11. PubMed ID: 24725395
[TBL] [Abstract][Full Text] [Related]
38. IL-12 suppresses vascular endothelial growth factor receptor 3 expression on tumor vessels by two distinct IFN-gamma-dependent mechanisms.
Sorensen EW; Gerber SA; Frelinger JG; Lord EM
J Immunol; 2010 Feb; 184(4):1858-66. PubMed ID: 20061409
[TBL] [Abstract][Full Text] [Related]
39. The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies.
Muller PY; Milton M; Lloyd P; Sims J; Brennan FR
Curr Opin Biotechnol; 2009 Dec; 20(6):722-9. PubMed ID: 19896825
[TBL] [Abstract][Full Text] [Related]
40. Angiostatin anti-angiogenesis requires IL-12: the innate immune system as a key target.
Albini A; Brigati C; Ventura A; Lorusso G; Pinter M; Morini M; Mancino A; Sica A; Noonan DM
J Transl Med; 2009 Jan; 7():5. PubMed ID: 19144161
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
